NASDAQ:SIENSientra Stock Price, Forecast & News

Sientra's stock was trading at $2.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SIEN shares have increased by 57.4% and is now trading at $3.84. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sientra.

Sientra is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Sientra.

Sientra Inc (NASDAQ:SIEN) released its quarterly earnings data on Monday, May, 11th. The medical instruments supplier reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.08. The medical instruments supplier had revenue of $16.93 million for the quarter, compared to the consensus estimate of $18.70 million. Sientra had a negative return on equity of 101.94% and a negative net margin of 134.87%. View Sientra's earnings history.

Sientra updated its FY 2020 After-Hours earnings guidance on Wednesday, March, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $94-98 million, compared to the consensus revenue estimate of $101.66 million.

7 Wall Street analysts have issued 12-month target prices for Sientra's shares. Their forecasts range from $5.00 to $10.00. On average, they expect Sientra's stock price to reach $7.05 in the next year. This suggests a possible upside of 83.6% from the stock's current price. View analysts' price targets for Sientra.

Press coverage about SIEN stock has been trending positive this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sientra earned a coverage optimism score of 2.7 on InfoTrie's scale. They also gave news stories about the medical instruments supplier a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutSientra.

Sientra saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,090,000 shares, an increase of 25.6% from the April 30th total of 2,460,000 shares. Based on an average trading volume of 1,430,000 shares, the days-to-cover ratio is currently 2.2 days. Currently, 7.2% of the shares of the stock are sold short. View Sientra's Current Options Chain.

Some companies that are related to Sientra include Establishment Labs (ESTA), Invacare (IVC), RTI Surgical (RTIX), Lakeland Industries (LAKE), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Allied Healthcare Products (AHPI), Histogenics (HSGX), Ocugen (OCGN), Rewalk Robotics (RWLK), Precision Therapeutics (POAI), Bionik Laboratories (BNKL), NanoVibronix (NAOV) and Avitar (AVTI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sientra investors own include Micron Technology (MU), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Alibaba Group (BABA), Genocea Biosciences (GNCA), AT&T (T), Viking Therapeutics (VKTX), Verizon Communications (VZ), Anavex Life Sciences (AVXL) and salesforce.com (CRM).

Sientra trades on the NASDAQ under the ticker symbol "SIEN."

Sientra's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.44%), UBS Group AG (4.85%), Schroder Investment Management Group (3.80%), JPMorgan Chase & Co. (2.31%), Granahan Investment Management Inc. MA (1.62%) and State Street Corp (1.40%). Company insiders that own Sientra stock include Jeffrey M Nugent, Keith J Sullivan, Paul Sean Little and Timothy Haines. View institutional ownership trends for Sientra.

SIEN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Bank of New York Mellon Corp, Deutsche Bank AG, Spark Investment Management LLC, BlackRock Inc., State Street Corp, Two Sigma Investments LP, and Blair William & Co. IL. View insider buying and selling activity for Sientra.

SIEN stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Nuveen Asset Management LLC, AQR Capital Management LLC, Granahan Investment Management Inc. MA, Geode Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., SG Americas Securities LLC, and UBS Group AG. Company insiders that have bought Sientra stock in the last two years include Keith J Sullivan, and Paul Sean Little. View insider buying and selling activity for Sientra.

Shares of SIEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SIEN stock can currently be purchased for approximately $3.84.

Sientra has a market capitalization of $192.12 million and generates $83.70 million in revenue each year. The medical instruments supplier earns $-106,820,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis. Sientra employs 339 workers across the globe.

The official website for Sientra is www.sientra.com.

Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The medical instruments supplier can be reached via phone at 805-562-3500 or via email at [email protected]